Announced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data expected in…
August 01, 2025 17:06 ET | Source: Taysha Gene Therapies, Inc. DALLAS, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Taysha Gene…
July 25, 2025 16:15 ET | Source: Portage Biotech Inc. DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech…
SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., July 25,…
SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing…
July 02, 2025 03:00 ET | Source: Belite Bio, Inc - 500 subjects enrolled across the United States, the United…
Phase 1 data evaluating VRB-101, Verdiva Bio’s cAMP-biased oral GLP-1RA, provides proof of concept for potential once-weekly oral administration. Preclinical…
June 20, 2025 19:30 ET | Source: Structure Therapeutics Inc. SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics…
June 19, 2025 01:00 ET | Source: Addex Therapeutics Strong cash position of CHF2.8 million at end of Q1 2025GABAB…
June 18, 2025 01:00 ET | Source: Addex Therapeutics Geneva, Switzerland, June 18, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a…